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Abstract
Background: Chemotherapeutic drug efflux via the P-glycoprotein (P-gp) transporter encoded by
the MDR1/ABCB1 gene is a significant cause of drug resistance in numerous malignancies, including
acute leukemias, especially in older patients with acute myeloid leukemia (AML). Therefore, the P-
gp modulators that block P-gp-mediated drug efflux have been developed, and used in combination
with standard chemotherapy. In this paper, the capacity of zosuquidar, a specific P-gp modulator,
to reverse chemoresistance was examined in both leukemia cell lines and primary AML blasts.
Methods: The transporter protein expressions were analyzed by flow cytometry using their
specific antibodies. The protein functionalities were assessed by the uptake of their fluorescence
substrates in presence or absence their specific modulators. The drug cytotoxicity was evaluated
by MTT test.
Results:  Zosuquidar completely or partially restored drug sensitivity in all P-gp-expressing
leukemia cell lines tested and enhanced the cytotoxicity of anthracyclines (daunorubicin, idarubicin,
mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) in primary AML blasts with active P-gp. In
addition, P-gp inhibition by zosuquidar was found to be more potent than cyclosporine A in cells
with highly active P-gp.
Conclusion: These in vitro studies suggest that zosuquidar may be an effective adjunct to cytotoxic
chemotherapy for AML patients whose blasts express P-gp, especially for older patients.
Background
Outcomes for patients with acute myeloid leukaemia
(AML), particularly those over age 60 years, have not sig-
nificantly improved in the past 20 years and conventional
cytarabine and anthracycline-based chemotherapy
remains the gold standard. Despite the activity of these
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agents, 20% of patients ≤ 60 years and 50% of older
patients fail to achieve remission with these standard
agents, and only a small proportion patients have a pro-
longed disease-free survival [1]. Chemoresistance to
standard agents has been shown to be related, in part, to
overexpression of P-gp, one of the best characterized
multidrug resistance (MDR) ABC proteins. P-gp functions
by pumping certain drugs out of cells through an active,
energy dependent mechanism [2-4].
P-gp expression tends to be increased in older patients
with AML and likely contributes to their poor response to
induction chemotherapy. Therefore, significant interest
has developed in combining modulators that block P-gp-
mediated drug efflux with standard chemotherapy regi-
mens. However, randomized trials of P-gp modulators
such as cyclosporine A (CsA) and PSC-833 in relapsed or
refractory AML patients have had variable results [5-7].
One of the challenges of the use of CsA and PSC-833 has
been lack of specificity. In addition to P-gp modulation,
both drugs also alter the pharmacokinetic profiles and
decrease the clearance of co-administrated chemothera-
peutic agents. It has been suggested that the decreased
clearance results from modulation of several ABC trans-
porters at hepatic level, as well as altered regulation of
cytochrome P450 metabolic enzymes such as CYP3A4 or
CYP2C8 [8,9]. As a result, the doses of the chemothera-
peutic agents that are substrates for P-gp (DNR, mitox-
antrone, etoposide) was reduced by 22% to 66% when
used in combination trials with CsA and PCS-833 to avoid
excessive toxicity [7,10,11]. In contrast, zosuquidar, a
highly specific P-gp inhibitor, which does not interact
with other transporters including MRP1, MRP2 and
mutant BCRP (R482T) [12], has been developed in an
attempt to avoid significant pharmacokinetic interactions
and therefore allow co-administration of standard dosing
of cytotoxic chemotherapy. Zosuquidar has significantly
lower affinity for CYP3A than for P-gp [13] and phase I tri-
als have shown that zosuquidar can be given safely to the
AML patients in combination with daunorubicin and
cytarabine [14,15]. In addition to the conventional cytara-
bine and anthracycline-based chemotherapy, Mylotarg is
a novel immunoconjugate therapy for acute myeloid
leukemia (AML). P-glycoprotein (Pgp) has been shown to
confer resistance to Mylotarg and is associated with a
worse clinical response. In vitro studies have been showed
that inhibition of Pgp function by CsA could restore Mylo-
targ sensitivity [16,17]. Zosuquidar, a Pgp specific inhibi-
tor, can probably also restore Mylotarg sensitivity.
In this study, we investigate the ability of zosuquidar to
reverse resistance to several chemotherapeutic agents
which are P-gp substrates and used in the AML treatments
or AML trials as well as the capacity of zosuquidar to
restore drug sensitivity in a panel of myeloid leukemia cell
lines with different levels of P-gp activity. Clinically, it will
be important to identify AML patients whose blasts pos-
sess high P-gp activity, as this subgroup will be most likely
to benefit from combination therapy with zosuquidar.
Therefore, we studied the correlation between P-gp activ-
ity in primary AML patient blasts and in vitro chemosen-
sitization by zosuquidar.
Methods
Cell lines
The studies were carried out with human Bcr-abl myeloid
leukemia cells (K562), human myeloid leukemia cells
(HL60) and six variant cell lines expressing P-gp, MRP1,
or BCRP: K562/HHT40, K562/HHT90 (developed in our
laboratory) [18], K562/DOX, K562/BCRP (gift from Y.
Suquimoto, Foundation for Cancer Research, Japan) [19],
HL60/DNR and HL60/ADR. Cells were cultured in RPMI
1640 medium containing 10% fetal calf serum (FCS),
penicillin 50 U/ml, and streptomycin 50 µg/ml and incu-
bated in a humidified atmosphere containing 5% CO2 at
37°C.
AML patient samples
Peripheral blood samples from 31 AML patients were
obtained after their informed consent. Mononuclear cells
(MNC) were isolated using Ficoll-Hypaque density gradi-
ent. The primary AML blasts were cultured under the same
general conditions as described above for the cell lines.
Ethical approval
The present study carried out on human blood cells is in
compliance with the Helsinki Declaration, and was
approved by the French Institute National of Cancer
(Tumo06). AML patient blood samples were obtained
after their informed consent (Formulary EORTC study N°
06012).
P-gp, MRP1, MRP3 and BCRP expression analysis
P-gp, MRP1, MRP3 and BCRP expression was studied by
using UIC2 (P-gp, Immunotech, France), QCRL3 (MRP1),
MRP3 and Bxp21 (BCRP) monoclonal antibodies (all
from Alexis, CA, USA), then labeled with a secondary anti-
body conjugated with phycoerythrin. Cells (1 × 106) were
fixed and permeabilized using IntraPrep™ (Beckman
Coulter, Villepinte, France) according to the instructions
of the manufacturer. The fluorescence was measured and
analyzed by flow cytometry. Protein expression for each
transporter was quantified as the mean fluorescence
intensity (MFI) shift (ratio of the MFI of antibody and iso-
type control). All experiments were performed in tripli-
cate.
P-gp, MRP1 and BCRP activity analysis
Cells (1 × 106) were incubated with 25 nM DiOC2(3) or
0.2 µg/ml rhodamine at 37°C for 30 min in presence orBMC Cancer 2008, 8:51 http://www.biomedcentral.com/1471-2407/8/51
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absence of either 0.3 µM zosuquidar (Kanisa, USA) or 2
µM CsA for P-gp activity analysis, with 0.2 µM Calcein-AM
(C-AM)(Molecular probes, USA) in presence or absence of
5 µM MK571 for MRP1 activity analysis, and with 3 µM
mitoxantrone (Mitox) in presence or absence of 10 µM
Fumitrimorgin C (FTC) (Alexis Biochemicals, USA) for
BCRP activity analysis. Cells were immediately analyzed
by flow cytometry. Dye uptake was expressed as D value
ranging from 0 (no difference) to 1 (no overlap) gener-
ated by Kolmogorove-Smirnov test which was used to
determine the distribution of the MFI between presence
and absence of modulator. For each sample, 5000 events
were collected. All experiments were performed in tripli-
cate.
Cell viability study (MTT assay)
Cells (2 × 104 cells/well for cell line, 4 × 105 cells/well for
patient cells) were cultured in 96-well plates. Each drug of
interest was added at escalating concentrations in the
presence or absence of either zosuquidar or CsA. After 48
hour incubation (except Mylotarg, 4 days incubation), 20
µl of MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide) was added to each well for a
further 4 hour incubation. The purple precipitate was dis-
solved in 200 µl DMSO, and the optic density (OD) was
determined by the multi-well plate reader (Multiskan
Ascent, Labsystems). Each condition was repeated in four
wells, and result expressed as the mean of the four wells.
The viability is expressed as the ratio of the OD of the cells
in presence of each drug at different concentration with or
without modulator and the OD of control cells in media
without drug. The IC50 (the half maximal inhibitory con-
centration) was determined by Software (Biosoft, Cam-
bridge, UK) following the viability results. All experiments
were performed in triplicate.
Statistical analysis
The statistical analysis was performed by the statistical dis-
covery software (JMP5.1) en using student's t-test of com-
parisons for each pair.
Results
Protein expression of P-gp, MRP1, MRP3 and BCRP in 
K562, HL60 and variant cell lines
First, P-gp expression was evaluated in K562, HL60 and
variant cell lines. P-gp expression in resistant variant cell
lines K562/HHT40, K562/HHT90 and K562/DOX, was
increased compared to parental K562S cells (MFI = 0.98 ±
0.17), with MFI shifts of 2.48 ± 0.60, 3.24 ± 0.80, and
11.58 ± 3.42 respectively. HL60/DNR cells expressed
strongly P-gp (19.30 ± 4.79), but HL60/ADR cells did not
show significant higher P-gp expression (1.50 ± 0.44)
than parental HL60/S cells (1.14 ± 0.27) (Figure 1A).
Second, in order to characterize whether there is a cross-
resistance in these cell lines, MRP1, MRP3, and BCRP
P-gp, MRP1, MRP3 and BCRP expression in K562, HL60 and their variant resistant cell lines Figure 1
P-gp, MRP1, MRP3 and BCRP expression in K562, HL60 and their variant resistant cell lines. A) P-gp expression 
was analyzed by UIC2 monoclonal antibody. B) MRP1, MRP3 and BCRP were analyzed respectively by their specific mono-
clonal antibodies QCRL3 (white), MRP3 (grey) and Bxp21 (black).BMC Cancer 2008, 8:51 http://www.biomedcentral.com/1471-2407/8/51
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expression was also studied. The expression of MRP1 was
similar in these cell lines with a few exceptions. MRP1
expression in HL60/ADR and HL60/DNR was higher than
the HL60 parental cell line with MFI shifts of 3.50 ± 2.84
and 3.81 ± 2.44 respectively. No significant MRP3 or
BCRP expression was observed in any cell lines tested (Fig-
ure 1B).
P-gp, MRP, and BCRP activity in K562, HL60 and variant 
cell lines
In some cases, the ABC protein expression does not con-
duct to their capacity to transport their substrate in cells.
Therefore, we have examined P-gp, MRP1 and BCRP activ-
ity in those cell lines. P-gp activity was assessed by the
uptake of two different fluorescent substrates DiOC2(3)
and rhodamine in the presence or absence of either zosu-
quidar or CsA. The results are displayed in Figure 2. The
values of P-gp activity measured by the uptake of
DiOC2(3) ± zosuquidar or CsA as modulator were similar
to that measured by the uptake of Rhodamine. P-gp activ-
ity of K562/HHT40, K562/HHT90 and K562/DOX cells
was increased compared to the parental K562 cells. Inter-
estingly, HL60/DNR cells showed very high P-gp activity,
while HL60/ADR cells had similar P-gp activity to paren-
tal HL60 cells. These P-gp activity results or pump activi-
ties correlate closely with P-gp protein expression.
BCRP and MRP activity was analyzed by the uptake of
their corresponding substrates (Mitox and C-AM), in the
presence or absence of their respective specific modulators
(FTC and MK571). Only HL60/ADR cells exhibited signif-
icant MRP activity (D = 0.91 ± 0.04) (Figure 3). This cor-
relates with the finding of significant MRP protein
expression in this cell line compared to the other cell lines
evaluated. But HL60/DNR cells did not exhibit significant
P-gp activity in K562, HL60 and their variant resistant cell lines Figure 2
P-gp activity in K562, HL60 and their variant resistant cell lines. P-gp activity was measured by the uptake of 
DiOC2(3) and rhodamine in either presence or absence of either zosuquidar (grey) or CsA (black). Two examples histograms 
K562 versus K562/Dox and HL60 versus HL60/DNR are presented in this figure.BMC Cancer 2008, 8:51 http://www.biomedcentral.com/1471-2407/8/51
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MRP activity (0.09 ± 0.04). No cell line demonstrated sig-
nificant BCRP activity (Figure 3).
Modulation of drug resistance in K562 and HL60 variant 
cell lines
The effects of zosuquidar and CsA on the cytotoxicity of
several drugs currently used in the treatment of AML or in
clinical investigation for AML therapy were examined in
these escalating resistant cell lines. The chemotherapy
agents evaluated were daunorubicin (DNR), idarubicin,
mitoxantrone, semi-synthetic HHT (Stragen Pharma,
Geneva, Switzerland) and Mylotarg (Wyeth-Lederle,
USA). Mylotarg was not be able to study in K562 and their
variant cell lines, because those cell lines are CD33-. The
IC50 of those agents on K562 and HL60 variant cell lines
were assessed by MTT assay. The efficacy of P-gp modula-
tion was described by a resistance modifying factor (RMF:
ratio of IC50 in the presence of zosuquidar or CsA over the
IC50 in the absence of the P-gp inhibitor). As shown in
Table 1, zosuquidar had a greater impact than CsA on
drug sensitivity in K562/DOX and HL60/DNR, the two
cell lines which express the greatest P-gp activity. For
example, 0.3 µM of zosuquidar enhanced the cytotoxicity
of DNR in K562/DOX cells more than 45.5-fold; the DNR
IC50 decreased from more than 50 µM to 1.1 ± 0.4 µM in
the presence of zosuquidar while 2 µM of CsA enhanced
the cytotoxicity of DNR in K562/DOX cells only more
than 4.8-fold, with the DNR IC50 decreasing to 10.5 ± 1.6
µM in the presence of CsA.
Zosuquidar enhanced the cytotoxicity of DNR in P-gp
active cell lines (K562/HHT40, K562/HHT90, K562/DOX
and HL60/DNR) but not the MRP active cell line, HL60/
ADR. These data indicate that zosuquidar selectively mod-
ulates P-gp-mediated resistance. Curiously, zosuquidar
enhanced the cytotoxicity of mitoxantrone in two parental
cells, K562 and HL60. The viability of these cells with
zosuquidar alone was verified to demonstrate that the
enhanced cytotoxicity of mitoxantrone in K562 and HL60
cells is not due to toxicity from zosuquidar itself. The rea-
son for this response to Mitox in K562 and HL60 cells is
unknown.
Lack of effect of zosuquidar on wild type BCRP-expressing 
cells
Daunorubicin and idarubicin are transported by mutant
BCRP (R482T or R482G) and not by wild type BCRP
(R482), while mitoxantrone is transported by all BCRP
variants [20]. It has been shown that zosuquidar did not
affect on the mutant BCRP (R482T) mediated drug trans-
port [21]. To assess the effect of zosuquidar on wild type
BCRP-mediated drug transport, we evaluated the accumu-
lation of mitoxantrone in K562/BCRP cells that were
transfected with wild type BCRP compared to parental
K562S cells. Mitoxantrone accumulation in K562/BCRP
cells with Zosuquidar treatment was compared to the
BCRP specific modulator FTC. 10 µM of FTC enhanced
the uptake of mitoxantrone in K562/BCRP cells, while
zosuquidar had no effect (D = 0.59 ± 0.11 vs D = 0.04 ±
0.07) (Table 2).
Modulation of drug resistance by zosuquidar in AML 
patient cells
To determine whether zosuquidar could enhance the
chemotherapeutic drug cytotoxicity in primary AML
blasts, the effects of zosuquidar on the cytotoxicity of dau-
norubicin, idarubicin, mitoxantrone, and Mylotarg were
examined in 31 AML patient cells. The characteristics of
31 patients are shown in Table 3. In parallel, we analyzed
cellular uptake of DIOC2(3) in these samples. The effects
of CsA on cytotoxicity could not be compared to zosuqui-
dar because CsA alone caused death of 40% to 60% of the
primary AML blasts after 48 hour culture. The results in
Table 4 present in detail the modulation of cytotoxicity by
zosuquidar and the P-gp activity measured by the uptake
of DIOC2(3) in those 31 patient cells. Zosuquidar
enhanced drug cytotoxicity in 8 of 31 AML cases (26%);
among these 8 cases, five cases demonstrated significant
P-gp activity (D > 0.3) as determined by cellular uptake of
DIOC2(3). Among the 31 AML samples evaluated, signif-
icant P-gp activity was found in 7 of 31 (23%); zosuquidar
enhanced drug cytotoxicity in 5 of these 7 (71%), all of
which were older patients > 60 years of age. 24 of 31 AML
samples showed no P-gp activity; in 21 of these 24 sam-
ples, zosuquidar had no effect on cytotoxicity when com-
MRP1 and BCRP activity in K562, HL60 and their variant  resistant cell lines Figure 3
MRP1 and BCRP activity in K562, HL60 and their 
variant resistant cell lines. MRP1 and BCRP activity was 
measured by the uptake of Calcein-AM and Mitox in pres-
ence or absence of their specific modulators MK571 (grey) 
and FTC (black).BMC Cancer 2008, 8:51 http://www.biomedcentral.com/1471-2407/8/51
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bined with chemotherapy. When the samples were
divided into two groups based on the ability of zosuqui-
dar to enhance chemotherapeutic cytotoxicity (8 samples
with increased cytotoxicity, 23 samples without modifica-
tion of cytotoxicity), DIOC2(3) uptake was significantly
different between the two groups (p < 0.004 by Student's
t-test) (Table 5).
Discussion
Multidrug resistance can also result from the overexpres-
sion of other member of the ABC transporter family such
as MRP1 and BCRP. Overexpression of MRP1 can confer
resistance to DNR, doxorubicin, idarubicin, Mitox, HHT
and Mylotarg. As for BCRP, its overexpression can also
confer resistance to DNR, doxorubicin, idarubicin, Mitox.
To verify whether these cells are cross-resistant to those
agents, we have well characterized Pgp, MRP1, MRP3 and
BCRP expression and activity, which have been shown
involving in the chemoresistance of AML treatment
[4,22], in K562, HL60 and their derivation cell lines. Non
cross-resistance was observed in these cells. In addition,
K562 and its derivation cell lines having escalated P-gp
activity provide us a good model for this study. These in
vitro  investigations demonstrate that zosuquidar is a
highly potent modulator of P-gp-mediated drug resist-
ance. Zosuquidar (0.3 µM) completely or partially
restored sensitivity to daunorubicin, idarubicin, mitox-
antrone, HHT, and Mylotarg in K562/HHT40, K562/
HHT90, K562/DOX and HL60/DNR cells, all of which
express P-gp. Zosuquidar was more effective than CsA in
enhancing cytotoxicity in the two cell lines with the high-
est P-gp activity, K562/DOX and HL60/DNR. As it was
Table 2: Effect of zosuquidar on mitoxantrone accumulation in 
K562/BCRP and K562/Vec cells
FTC (10 µM) Zosuquida
K562/Vec 0 0
K562/BCRP 0.59 ± 0.11 0.04 ± 0.07
Table 1: Modulation of cytotoxicity of K562, HL60 and their variant resistant cells
DNR Idarubicin Mitox HHT Mylotarg
IC50 (µM) RMF IC50 (µM) RMF IC50 (µM) RMF IC50 (ng/ml) RMF IC50 (ng/ml) RMF
K562
None 0.28 ± 0.09 0.071 ± 0.026 0.60 ± 0.21 57.3 ± 6.5
Zosuquidar 0.26 ± 0.09 1.1 0.071 ± 0.042 1.0 0.095 ± 0.029 6.3 58.4 ± 10.1 1.0
CsA 0.23 ± 0.12 1.2 0.068 ± 0.039 1.0 0.14 ± 0.05 4.3 56.6 ± 4.2 1.0
K562/HHT40
None 2.3 ± 0.2 0.27 ± 0.06 1.7 ± 0.2 197.6 ± 44.4
Zosuquidar 0.66 ± 0.08 3.5 0.20 ± 0.07 1.4 0.33 ± 0.06 5.2 85.4 ± 2.9 2.3
CsA 0.51 ± 0.08 4.5 0.24 ± 0.11 1.1 0.45 ± 0.06 3.8 91.3 ± 9.3 2.2
K562/HHT90
None 3.6 ± 1.5 0.17 ± 0.11 1.9 ± 0.9 409.6 ± 70.2
Zosuquidar 0.37 ± 0.14 9.7 0.12 ± 0.09 1.4 0.13 ± 0.05 14.6 80.4 ± 8.3 5.8
CsA 0.32 ± 0.19 11.3 0.10 ± 0.06 1.7 0.25 ± 0.18 7.6 81.8 ± 8.3 5.0
K562/DOX
None >50b 1.82 ± 0.17 >50 >720
Zosuquidar 1.1 ± 0.4 >45.5 0.21 ± 0.03 8.7 0.53 ± 0.10 >94.3 88.8 ± 1.9 >8.1
CsA 10.5 ± 1.6 >4.8 0.30 ± 0.10 6.1 4.29 ± 0.22 >11.7 639.1 ± 70.1 >1.1
HL60
None 0.16 ± 0.03 0.053 ± 0.004 0.48 ± 0.22 40.5 ± 5.2 131.9 ± 72.3
Zosuquidar 0.13 ± 0.04 1.2 0.057 ± 0.008 0.9 0.09 ± 0.03 5.3 41.7 ± 3.1 1.0 83.8 ± 9.5 1.6
CsA 0.10 ± 0.02 1.6 0.033 ± 0.008 1.6 0.13 ± 0.07 3.7 33.6 ± 2.6 1.2 35.5 ± 1.0 3.7
HL60/ADR
None 2.1 ± 0.4 0.51 ± 0.03 1.5 ± 0.2 60.7 ± 12.4 >2000
Zosuquidar 2.4 ± 0.5 0.9 0.50 ± 0.03 1.0 1.4 ± 0.4 1.1 58.6 ± 4.6 1.0 >2000 ND
CsA 0.49 ± 0.04 4.3 0.30 ± 0.09 1.7 0.51 ± 0.03 2.9 48.7 ± 5.3 1.2 67.6 ± 7.6 >29.9
HL60/DNR
None >40 0.51 ± 0.05 >20 489.9 ± 24.5 >2000
Zosuquidar 0.49 ± 0.16 >81.6 0.14 ± 0.01 3.6 0.22 ± 0.06 >90.1 46.5 ± 9.7 10.5 620.5 ± 38.9 3.2
CsA 2.5 ± 0.8 >16 0.15 ± 0.00 3.4 1.4 ± 0.6 >14.3 60.3 ± 5.0 8.1 >2000 ND
a. All values are the means determined in quadruplicate in three independent experiments.
b. The maximal dose tested was 50 µM. IC50 was more than 50 µM, not determined.
c. Zosuquidar = 0.3 µM, CsA = 2 µM.BMC Cancer 2008, 8:51 http://www.biomedcentral.com/1471-2407/8/51
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already described, IC50 of idarubicin was poorly modi-
fied for cell lines by P-gp inhibitors. In the other hand, P-
gp efflux in clinical samples had a negative impact on
complete remission achievement in patients treated with
idarubicin [23].
It has been shown that zosuquidar did not affect on the
mutant BCRP (R482T) mediated drug transport [21]. In
this paper we have shown that Zosuquidar does not affect
on the wild type BCRP mediated drug transport, it selec-
tively modulates P-gp-mediated resistance, but has no
effect on MRP or wild type BCRP-mediated resistance.
Zosuquidar enhanced the cytotoxicity of mitoxantrone in
two parental cells, K562 and HL60. The reason for this
response to Mitox in K562 and HL60 cells is unknown. It
is possible that other non identified ABC proteins confer
Mitox resistance in these two cell lines. It needs the further
investigations.
The in vitro studies of primary AML blasts demonstrate
that zosuquidar enhanced the cytotoxicity of daunoru-
bicin, idarubicin, mitoxantrone, or Mylotarg in the major-
ity of AML cases which expressed active P-gp. These results
suggest that zosuquidar may have great potential as a
chemosensitizing agent in combination with a number of
standard agents for AML patients whose blasts express P-
gp. Several clinical trials have given the encouraging
results [14,15,24]. The clinical phase I trial of zosuquidar,
co-administered with daunorubicin and cytosine arabino-
side (ARA-C) on sixteen patients with AML [15] has
shown that eleven patients achieved a complete remission
and one a partial remission with a median survival of 559
(range 38–906) days. Non-hematologic grade 3 and 4 tox-
icities were seen in 4 patients. Zosuquidar infusion was
associated with rapid inhibition of Rh123 efflux in CD56+
cells in 16/16 patients and in CD33+ cells in 6/10 patients.
Other clinical trials in patients with non-Hodgkin's lym-
phoma [24] and patients with advanced malignancy [14]
have shown also that zosuquidar did not significantly
affect the pharmacokinetics of doxorubicin and had mod-
erate effects on the pharmacokinetics of vincristine. These
clinical trials approved that zosuquidar could safely
administrated with daunorubicin, doxorubicin and other
regimens. Zosuquidar is potent, specific, and avoids the
pharmacokinetic interactions that limit the use of other P-
gp inhibitors. P-gp expression is particularly frequent in
AML patients older than age 60 years, a subgroup of
patients with poor induction response and long-term out-
comes. This patient subgroup may particularly benefit
from treatment strategies combining chemotherapy with
zosuquidar and phase II trials are currently ongoing.
Conclusion
Zosuquidar completely or partially restored drug sensitiv-
ity in all P-gp-expressing leukemia cell lines tested and
enhanced the cytotoxicity of anthracyclines (daunoru-
bicin, idarubicin, mitoxantrone) and gemtuzumab ozo-
gamicin (Mylotarg) in primary AML blasts with active P-
gp. In addition, the cytotoxicity enhanced by Zosuquidar
was found to be more potent than that by cyclosporine A
in cells with highly active P-gp. These in vitro studies sug-
gest that zosuquidar may be an effective adjunct to cyto-
toxic chemotherapy for AML patients whose blasts express
P-gp, especially for older patients than age 60 years.
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Table 3: Characteristics of patients
Age Mean ± SD (range) 60 ± 17 y (22–81)
Leukocyte (109/L) 46 ± 44 (3.2–184)
FAB subtypes
1 23% (7/31)
2 23% (7/31)
4 16% (5/31)
5 13% (4/31)
Myelodysplastic syndrome 26% (8/31)
Karyotype
Favorable 6% (2/31)
Intermediate 71% (22/31)
Poor 19% (6/31)
Not done 3% (1/31)
CD34
Positive 55% (17/31)
Negative 42% (13/31)
Not done 3% (1/31)
P-gp activity
Mean D ± SD (range) 0.1 ± 0.1 (0–0.7)
Positive D > 0.3 23% (7/31)
Negative D < 0.3 77% (24/31)
Table 5: Effect of zosuquidar to the cytotoxicity of DNR, Mitox 
and Mylotarg in 31 AML patient cells
Modulation* No modulation
Active P-gp (D > 0.3) 71% (5/7) 29% (2/7)
No active P-gp (D < 0.3) 13% (3/24) 87% (21/24)
Modulation* means the enhanced cytotoxicity with zosuquidar.BMC Cancer 2008, 8:51 http://www.biomedcentral.com/1471-2407/8/51
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